Dr Sally Martin

Sally Martin
Post Doctoral - Researcher
Adelaide Medical School
Faculty of Health and Medical Sciences

Dr Martin is currently a post-doctoral researcher in the Myeloma Research Laboratory, School of Medical Sciences, University of Adelaide, based at the SAHMRI, Cancer Theme.

Dr Martin's PhD research, completed in 2009, centred on bone marrow angiogenesis and osteolytic bone disease in the haematological malignancy, multiple myeloma. Since completing her PhD studies, Dr Martin has been examining the role of the PI3K and mTOR signalling pathways in bone development, looking at ways to exploit these pathways to stimulate bone formation in disease settings such as osteoporosis and tumour-associated bone loss.

Dr Martin is an affiliate lecturer in the School of Medical Sciences and the School of Medicine, University of Adelaide.

Dr Martin's current research projects are focussed on (1) the role of the mTOR signalling pathways in mesenchymal stem cell biology, (2) the role of the mTOR signalling pathways in regulating skeletal biology and bone remodelling, and (3) the role of skeletal mTORC1 signalling in B-cell development and glucose homeostasis.

Connect With Me

External Profiles

Dr Sally Martin

Dr Martin is currently a post-doctoral researcher in the Myeloma Research Laboratory, School of Medical Sciences, University of Adelaide, based at the SAHMRI, Cancer Theme.

Dr Martin's PhD research, completed in 2009, centred on bone marrow angiogenesis and osteolytic bone disease in the haematological malignancy, multiple myeloma. Since completing her PhD studies, Dr Martin has been examining the role of the PI3K and mTOR signalling pathways in bone development, looking at ways to exploit these pathways to stimulate bone formation in disease settings such as osteoporosis and tumour-associated bone loss.

Dr Martin is an affiliate lecturer in the School of Medical Sciences and the School of Medicine, University of Adelaide.

Dr Martin's current research projects are focussed on (1) the role of the mTOR signalling pathways in mesenchymal stem cell biology, (2) the role of the mTOR signalling pathways in regulating skeletal biology and bone remodelling, and (3) the role of skeletal mTORC1 signalling in B-cell development and glucose homeostasis.

Eligible to supervise Masters and PhD — email supervisor to discuss availability.

Appointments

Date Position Institution name
2015 Post-doctoral Researcher University of Adelaide, Adelaide
2013 Affiliate Lecturer University of Adelaide
2012 Affiliate Lecturer University of Adelaide
2009 - 2015 Post-doctoral Researcher SA Pathology
2003 - 2008 Technical Assistant (part-time) Institute of Medical and Veterinary Science (IMVS)

Education

Date Institution name Country Title
2005 - 2008 University of Adelaide, Adelaide Australia PhD
2000 - 2004 University of South Australia Australia Bachelor of Medical and Pharmaceutical Biotechnology (Hons)

Journals

Year Citation
2018 Tangseefa, P., Martin, S., Fitter, S., Baldock, P., Proud, C., & Zannettino, A. (2018). Osteocalcin-dependent regulation of glucose metabolism and fertility: Skeletal implications for the development of insulin resistance. Journal of Cellular Physiology, 233(5), 3769-3783.
DOI
2017 Vandyke, K., Zeissig, M., Hewett, D., Martin, S., Mrozik, K., Cheong, C., . . . Zannettino, A. (2017). HIF-2α promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1. Cancer Research, 77(20), 5452-5463.
DOI Scopus1 WoS1
2017 Fitter, S., Matthews, M., Martin, S., Xie, J., Ooi, S., Walkley, C., . . . Zannettino, A. (2017). mTORC1 plays an important role in skeletal development by controlling preosteoblast differentiation. Molecular and Cellular Biology, 37(7), e00668-1-e00668-20.
DOI Scopus4 WoS3 Europe PMC2
2015 Cheong, C., Chow, A., Fitter, S., Hewett, D., Martin, S., Williams, S., . . . Vandyke, K. (2015). Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Experimental Cell Research, 332(1), 24-38.
DOI Scopus8 WoS8 Europe PMC5
2015 Forristal, C., Brown, A., Helwani, F., Winkler, I., Nowlan, B., Barbier, V., . . . Levesque, J. (2015). Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML. Leukemia, 29(10), 2075-2085.
DOI Scopus10 WoS11 Europe PMC9
2015 Gan, Z., Fitter, S., Vandyke, K., To, L., Zannettino, A., & Martin, S. (2015). The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. European Journal of Haematology, 94(4), 343-354.
DOI Scopus14 WoS12 Europe PMC9
2015 Martin, S., Gan, Z., Fitter, S., To, L., & Zannettino, A. (2015). The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma. Leukemia Research, 39(3), 380-387.
DOI Scopus14 WoS13 Europe PMC11
2015 Martin, S., Fitter, S., Dutta, A., Matthews, M., Walkley, C., Hall, M., . . . Zannettino, A. (2015). Brief report: The differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation. Stem Cells, 33(4), 1359-1365.
DOI Scopus31 WoS27 Europe PMC26
2011 Martin, S., Diamond, P., Gronthos, S., Peet, D., & Zannettino, A. (2011). The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia, 25(10), 1533-1542.
DOI Scopus65 WoS62 Europe PMC57
2010 Williams, S., Martin, S., Vincent, C., Gronthos, S., Zheng, T., Atkins, G., & Zannettino, A. (2010). Circulating levels of TWEAK correlate with bone erosion in multiple myeloma patients. British Journal of Haematology, 150(3), 373-376.
DOI Scopus5 WoS5 Europe PMC2
2010 Martin, S., Diamond, P., Williams, S., To, L., Peet, D., Fujii, N., . . . Zannettino, A. (2010). Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica, 95(5), 776-784.
DOI Scopus51 WoS46 Europe PMC35
2010 Psaltis, P., Paton, S., See, F., Arthur, A., Martin, S., Itescu, S., . . . Zannettino, A. (2010). Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations. Journal of Cellular Physiology, 223(2), 530-540.
DOI Scopus86 WoS83 Europe PMC70
2010 Martin, S., Fitter, S., Bong, L., Drew, J., Gronthos, S., Shepherd, P., & Zannettino, A. (2010). NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. Journal of Bone and Mineral Research, 25(10), 2126-2137.
DOI Scopus38 WoS38 Europe PMC34
2009 Diamond, P., Labrinidis, A., Martin, S., Farrugia, A., Gronthos, S., To, L., . . . Zannettino, A. (2009). Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. Journal of Bone and Mineral Research, 24(7), 1150-1161.
DOI Scopus43 WoS44 Europe PMC31
2009 Labrinidis, A., Diamond, P., Martin, S., Hay, S., Liapis, V., Zinonos, I., . . . Evdokiou, A. (2009). Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clinical Cancer Research, 15(6), 1998-2009.
DOI Scopus27 WoS26 Europe PMC18
2006 Martin, S., Dewar, A., Farrugia, A., Horvath, N., Gronthos, S., To, L., & Zannettino, A. (2006). Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1α in patients with multiple myeloma. Clinical Cancer Research, 12(23), 6973-6977.
DOI Scopus20 WoS20 Europe PMC14
2005 Zannettino, A., Farrugia, A., Kortesidis, A., Manavis, J., To, L., Martin, S., . . . Gronthos, S. (2005). Elevated serum levels of stromal-derived factor-1α are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Research, 65(5), 1700-1709.
DOI Scopus140 WoS132 Europe PMC95
2004 Martin, S., To, L., Horvath, N., & Zannettino, A. (2004). Angiogenesis in multiple myeloma: Implications in myeloma therapy. Cancer Reviews: Asia-Pacific, 2(2), 119-129.
DOI

Mary Overton Early Career Research Fellowship (2012 - 2015), The role of the raptor and rictor signalling pathways in skeletal biology, AUD$252,000

Centre for Stem Cell Research Project Grant 2012, The role of raptor and rictor in MSC differentiation, AUD$75,000

Novartis Pharmaceuticals Project Grant 2011, Can the dual PI3K/mTOR inhibitor NVP-BEZ235 be used to stimulate bone formation in multiple myeloma? AUD$75,000.

Current Higher Degree by Research Supervision (University of Adelaide)

Date Role Research Topic Program Degree Type Student Load Student Name
2017 Co-Supervisor The role of osteoblast-mTORC1 in the regulation of glucose metabolism and male fertility Doctor of Philosophy Doctorate Full Time Miss Pawanrat Tangseefa

Past Higher Degree by Research Supervision (University of Adelaide)

Date Role Research Topic Program Degree Type Student Load Student Name
2013 - 2018 Co-Supervisor The Role of mTORC1 in Mesenchymal Stem Cell Fate Determination, Osteoblast Differentiation and Skeletal Development Doctor of Philosophy Doctorate Part Time Ms Mary Patricia Matthews
Position
Post Doctoral - Researcher
Phone
81284694
Campus
North Terrace West
Building
SAHMRI - South, floor 5
Org Unit
Medical Sciences

top